KL

Keith Lenden

Venture Partner, ARCH Venture Partners

San Carlos, California

Invests in

Stages:

  • Min Investment:

    $50,000.00
  • Max Investment:

    $150,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Venture Partner

    2017

    ARCH Venture Partners is a leading biotechnology and pharmaceutical venture capital firm

  • Co-Founder

    2018

    Autobahn Therapeutics is a CNS focused drug discovery and development company founded on technology from the Oregon Health & Science University

  • Co-Founder

    2018

    Boundless Bio is an ecDNA focused oncology drug discovery and development company founded on technology from the Ludwig Cancer Research Institute at UCSD

2011 - 2019

  • Co-Founder

    2011 - 2019

    Abide Therapeutics was a serine hydrolase inhibitor drug discovery and development company founded on technology from the Scripps Research Institute that was acquired by Lundbeck in 2019

2008 - 2015

  • Co-Founder

    2008 - 2015

    Receptos (NASDAQ: RCPT) was a GPCR drug discovery and development company founded on technology from the Scripps Research Institute and acquired by Celgene in 2015 (now BMS)

2013 - 2015

  • Vice President, Corporate Development & Strategy

    2013 - 2015

    Esperion Therapeutics (NASDAQ: ESPR) is a cardiovascular drug development company

2007 - 2013

  • Vice President, Product & Business Development

    2007 - 2013

    Maxygen was a biotechnology discovery and product development company

2004 - 2007

  • Senior Director, Business Development

    2004 - 2007

    Acologix was a renal focused drug development company

2001 - 2004

  • Director, Business Development

    2001 - 2004

    Genteric was a gene therapy and drug delivery company

1995 - 1999

  • Consultant

    1995 - 1999

    LEK Consulting is a leading biotechnology strategy consulting organization